Observational studyEBioMedicine2026
Survival of hypoxaemic patients treated with solar-powered oxygen in rural Somalia hospitals: a prospective, observational study.
Observational study in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Medical oxygen as essential health-system infrastructure in Somalia: A call for resilient and equitable access.African journal of emergency medicine : Revue africaine de la medecine d'urgence · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the coronavirus disease 2019 (COVID-19) pandemic, solar-powered oxygen concentrator systems were established in rural hospitals of conflict-affected, hard-to-reach regions in Somalia to address acute gaps in oxygen access. We assessed the outcome of treatment of patients and risk factors for death among patients receiving oxygen for hypoxaemia in these settings in Somalia.
methodsWe analysed data on all patients receiving medical oxygen for hypoxaemia in six rural hospitals in Somalia equipped with solar-powered oxygen concentrator systems during the pandemic. The endpoint of the analysis was death. We used the Kaplan-Meier survival analysis and the log-rank test to compare survival curves. We used Cox proportional hazard model to determine the predictors of death.
findingsWe included 1460 patients (age from 1 day to 90 years) with hypoxaemia (peripheral blood saturation level <90%) treated with solar-powered oxygen concentrator systems in six rural hospitals in Somalia between February 2021 and December 2023. There were 103 deaths, 22 of which occurred within 24 h of detection of hypoxaemia in the hospital. The Kaplan-Meier survival analysis showed the cumulative hazard of death at 1.5% (95% CI 1.1-2.3%) during the first 24 h of admission, 11.9% (95% CI 8.1-17.3%) on day 7 post-admission conditional on surviving the first 24 h. Patients aged 1-11 months had a significantly increased hazard of death (aHR 7.71 [95% CI 2.54-23.41]) while those admitted with birth asphyxia were 4 times more likely to die compared to patients with pneumonia (aHR 3.83 [95% CI 1.12-13.06]). Improved patient outcomes were associated with higher oxygen saturation levels on admission. One unit increase in SpO
interpretationThe availability of solar-powered oxygen concentrator systems can be a reliable solution to address oxygen insecurity in fragile, vulnerable health systems and conflict-affected countries, and can be associated with improved patient outcomes. Early detection and rapid initiation of oxygen therapy for hypoxaemic illness can support improved survival in patients of all ages, and with different conditions, if health care facilities without reliable electricity are fitted with solar-powered oxygen concentrator systems.
fundingThe authors have received no funding for this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.